Now that I am reassured, I will move on to the crux of the matter.
You talked about the price of drugs, the price of supply and the mechanism by which distributors are paid and drugs are delivered.
As I told the deputy minister earlier, drug prices have decreased in recent years. As a result, some distributors have less revenue, while the demand for drugs is increasing. Essentially, this is reducing margins and hurting the ability of companies to keep a reserve supply of drugs.
Can you explain how regulation, and particularly federal regulation of list prices, can contribute to further shortages?